By Fineline Cube 
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III SERENA-6 study for its camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist.
Study Details and Results
The study evaluated switching to camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor. The focus was on the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation. The camizestrant combination demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). While the key secondary endpoints of time to second disease progression (PFS2) and overall survival (OS) were immature at the time of this interim analysis, a trend in PFS2 benefit was observed.
Company Statement
“We are encouraged by the positive results of the SERENA-6 study,” said a spokesperson from AstraZeneca. “The significant improvement in progression-free survival highlights the potential of camizestrant to offer a new treatment option for patients with advanced breast cancer and ESR1 mutations.”
Future Trials and Assessments
Camizestrant is also being assessed for safety and efficacy in the SERENA-6, SERENA-4, CAMBRIA-1 and CAMBRIA-2 trials, either alone or combined with other drugs. These ongoing studies will further evaluate the potential of camizestrant in different treatment settings and patient populations.-Fineline Info & Tech